Please assess the completion status of the following clinical trial:

Trial Title: Budesonide 9 mg Capsules in Active UC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent,~* Men or women aged 18 to 75 years,~* Active ulcerative colitis, except proctitis limited to 15 cm ab ano, confirmed by endoscopy and histology,~* Established disease,~Exclusion Criteria:~* Crohn's disease, indeterminate colitis, ischaemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis, incomplete microscopic colitis), diverticular disease associated colitis,~* Toxic megacolon or fulminant colitis,~* Colon resection,~* Evidence of infectious colitis (e.g., pathogenic bacteria or Clostridium difficile toxin in stool culture at screening),~* Malabsorption syndromes,~* Celiac disease,~* Bleeding hemorrhoids,~* Active peptic ulcer disease~* Other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhea or gastrointestinal bleeding,~* Hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, or infection if careful medical monitoring is not ensured,~* Any severe infectious disease (e.g., tuberculosis, AIDS),~* Severe co-morbidity substantially reducing life expectancy,~* History of colorectal cancer,~* History of cancer (other than colorectal) in the last 5 years, except for basal cell carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).